A Extension Study to Evaluate the Safety and Efficacy of HRS-7249 in Patients With Hypertriglyceridemia
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 400 participants.
Also called NCT07799688
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 400 participants
- Registry
-
NCT07799688
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07799688. Randomized; no masking; primary purpose treatment. Start 2026-09-11 (actual); primary completion 2028-10-15 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Extension Study to Evaluate the Safety and Efficacy of HRS-7249 in Patients With Hypertriglyceridemia
- Condition
- Hyperlipidemia
- Intervention (Drug)
- HRS-7249 Injection
- Intervention (Drug)
- HRS-7249 Injection
- Lead sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct07799688- Content hash
a8e379441306cf4c0341135345d4097a21f0731efb6b2ef4ca598580b147df74